BioCryst: Q4 Earnings Snapshot
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $61.7 million in its fourth quarter.
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $61.7 million in its fourth quarter.
Suggested Reading
The Durham, North Carolina-based company said it had a loss of 31 cents per share. Losses, adjusted for non-recurring costs, came to 28 cents per share.
Related Content
The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.
The drugmaker posted revenue of $93.4 million in the period, exceeding Street forecasts. Five analysts surveyed by Zacks expected $89.2 million.
For the year, the company reported that its loss narrowed to $226.5 million, or $1.18 per share. Revenue was reported as $331.4 million.
BioCryst shares have declined roughly 5% since the beginning of the year. The stock has dropped 37% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX